Drugs / MTX
last change Jun 2014 re-read 2 minutes ago

MTX

Developed for
brain cancer
Investigated by
Deutsche Kinderkrebsstiftung · University Medical Center Hamburg-Eppendorf

Trials 1 · a red edge is where a trial was stopped

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02066220 Jun 2014 → Dec 2026 expected brain cancer University Medical Center Hamburg-Eppendorf Active not recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MTX MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46” NCT02066220
Route Other “MTX 2mg intraventricularly” NCT02066220